Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis

por Ghafouri, Sanaz N., Nayeri, Rebecca W., McAndrew, Nicholas P., Hurvitz, Sara A.
Publicado 2022

Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor

por Zhang, Jian, McAndrew, Nicholas P., Wang, Xiaojia, Du, Yiqun, DiCarlo, Brian, Wang, Mei, Chen, Kan, Yu, Wenlei, Hu, Xichun
Publicado 2023

Effects of systemic inflammation on relapse in early breast cancer

por McAndrew, Nicholas P., Bottalico, Lisa, Mesaros, Clementina, Blair, Ian A., Tsao, Patricia Y., Rosado, Jennifer M., Ganguly, Tapan, Song, Sarah J., Gimotty, Phyllis A., Mao, Jun J., DeMichele, Angela
Publicado 2021

A careful reassessment of anthracycline use in curable breast cancer

por Hurvitz, Sara Alsterlind, McAndrew, Nicholas P., Bardia, Aditya, Press, Michael F., Pegram, Mark, Crown, John P., Fasching, Peter A., Ejlertsen, Bent, Yang, Eric H., Glaspy, John A., Slamon, Dennis J.
Publicado 2021

Early treatment-related neutropenia predicts response to palbociclib

por McAndrew, Nicholas P., Dickson, Mark A., Clark, Amy S., Troxel, Andrea B., O’Hara, Mark H., Colameco, Christopher, Gallager, Maryann, Gramlich, Kristi, Zafman, Kelly, Vaughn, David, Schwartz, Gary K., O’Dwyer, Peter J., DeMichele, Angela
Publicado 2020

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer

por Makhlin, Igor, McAndrew, Nicholas P., Wileyto, E. Paul, Clark, Amy S., Holmes, Robin, Bottalico, Lisa N., Mesaros, Clementina, Blair, Ian A., Jeschke, Grace R., Fox, Kevin R., Domchek, Susan M., Matro, Jennifer M., Bradbury, Angela R., Feldman, Michael D., Hexner, Elizabeth O., Bromberg, Jacqueline F., DeMichele, Angela
Publicado 2022